SAB Biotherapeutics
SABS
22 hedge funds and large institutions have $9.7M invested in SAB Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
2.3% less ownership
Funds ownership: 36.18% → 33.88% (-2.3%)
8% less funds holding
Funds holding: 24 → 22 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
67% less capital inflows, than outflows
Capital inflows: $469K | Capital outflows: $1.41M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$367K |
| 2 |
First PREMIER Bank
Sioux Falls,
South Dakota
|
+$71.1K |
| 3 |
BlackRock
New York
|
+$27.2K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$3.51K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$605 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commodore Capital
New York
|
-$832K |
| 2 |
RTW Investments
New York
|
-$553K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$14.9K |
| 4 |
Millennium Management
New York
|
-$4.64K |
| 5 |
Spectrum Wealth Counsel
Indianapolis,
Indiana
|
-$2.28K |
SABS Hedge Fund Activity: Q2 2024 in Review
22 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2024, worth a combined $9.7M — down 36% from $15.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SABS and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $367K. The largest seller was Commodore Capital, exiting entirely with an estimated $832K sold.
- 22 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2024, down from 24 in Q1 2024.
- Funds reported $9.7M of SAB Biotherapeutics stock for Q2 2024, down 36% quarter-over-quarter.
- 2 funds opened new SAB Biotherapeutics positions in Q2 2024 and 4 closed out, a net change of -2 holders.
- The largest SAB Biotherapeutics buyer in Q2 2024 was Vanguard Group, an estimated $367K added.
- The largest SAB Biotherapeutics seller in Q2 2024 was Commodore Capital, an estimated $832K sold.
Based on aggregated 13F filings for Q2 2024.